While chemotherapy remains a cornerstone of lung cancer treatment, it often weakens the immune system it relies on for ...

Cisplatin-induced increase in active caspase-3 expression. A fluorescein active caspase-3 stain was used to detect the expression of activated caspase-3 in (a) UBOC1, (b) HK2, and (c) SH-SY5Y cell ...

Combination chemotherapy of cisplatin (or carboplatin as an alternative) + pemetrexed is the approved first-line standard of care. Phase 1 and 2 data suggest that targeting immune checkpoint pathways ...

Overall survival for cisplatin/pemetrexed was noninferior to cisplatin/gemcitabine (median survival, 10.3 v 10.3 months, respectively; HR = 0.94; 95% CI, 0.84 to 1.05). Overall survival was ...

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

DBL Cisplatin Injection is a platinum-containing medicine and is used as an anticancer drug to interfere with the growth of cancer cells and eventually destroy them. Cancer cells are like normal ...

Atorvastatin impacts cisplatin sensitivity in breast cancer cells by regulating key enzymes involved in cholesteryl-ester metabolism including acetyl-CoA acetyltransferase 1 (ACAT-1).

Severe acute toxic effects are listed in Table 2. During induction chemotherapy with cisplatin and fluorouracil, toxicity was manifested primarily as neutropenia, stomatitis, and nausea or vomiting.

Oncology nurses can assess patients’ risk factors and advocate for preventive strategies that protect kidney function during ...

Although cisplatin is clinically proven to combat numerous human cancers – bladder, head and neck, lung, ovarian, testicular – resistance to treatment remains a key challenge, and cisplatin patients ...

The Food and Drug Administration (FDA) has approved Pedmark ® (sodium thiosulfate) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with ...